16 research outputs found
68. Lymphome anaplasique Ă grandes cellules ALK- sur prothĂšse mammaire : un piĂšge clinique et anatomopathologique. Une nouvelle observation en 2013
74 â Changement du statut HER2 lors du passage des carcinomes canalaires in situ Ă lâinvasion : mythe ou rĂ©alitĂ© ?
60. HERFrance, observatoire national des pathologistes sur HER2, RO-RP et Ki-67 dans le cancer du sein â Bilan Ă un an sur 14 000 entrĂ©es
Accréditation et ACP
Issu des actes du Carrefour Pathologie 2010, symposium de l'Association française d'assurance qualité en anatomie pathologique (AFAQAP), 22-26 novembre 2010, Maison de la Chimie, Paris.International audienc
Mise Ă jour 2014 des recommandations du GEFPICS pour lâĂ©valuation du statut HER2 dans les cancers du sein en France
De nouvelles recommandations internationales pour lâĂ©valuation du statut HER2 dans les cancers du sein, basĂ©es sur plus de dix ans dâexpĂ©rience et sur les rĂ©sultats dâĂ©tudes cliniques et de concordance entre les diffĂ©rentes techniques de dĂ©tection, viennent tout juste de voir le jour. Le prĂ©sent article a pour objet de faire le point sur ces nouvelles recommandations, Ă la lumiĂšre de la publication rĂ©cente du groupe de travail de lâAmerican Society of Clinical Oncology (ASCO) et du CollĂšge des pathologistes amĂ©ricains (CAP), adaptĂ©es Ă la pratique de la pathologie en France et revues par le groupe GEFPICS. Ă lâĂšre de la mĂ©decine personnalisĂ©e, la dĂ©termination du statut HER2 reste un Ă©lĂ©ment phare dans le panel des biomarqueurs thĂ©ranostiques des cancers du sein. Si lâinterprĂ©tation du statut HER2 dans les cancers du sein est aisĂ©e dans la majoritĂ© des cas, un certain nombre de situations anatomocliniques est dâinterprĂ©tation plus dĂ©licate, telles que la possibilitĂ© rare mais rĂ©elle de lâhĂ©tĂ©rogĂ©nĂ©itĂ© intra-tumorale du statut de HER2, les formes Ă diffĂ©renciation micropapillaire ou la rĂ©-Ă©valuation du statut des biomarqueurs lors de la rechute mĂ©tastatique. Ces nouvelles recommandations abordent ces diffĂ©rentes questions, reprĂ©cisent les conditions prĂ©-analytiques optimales et les critĂšres dâinterprĂ©tation (notamment des cas 2+), afin de rĂ©duire au maximum le risque de faux nĂ©gatifs. Plus que jamais, la mobilisation de la spĂ©cialitĂ© dâanatomo-cytopathologie autour de la qualitĂ© des tests thĂ©ranostiques tĂ©moigne de son implication dans la chaĂźne des soins en cancĂ©rologie., Summary International guidelines on HER2 determination in breast cancer have just been updated by the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP), on the basis of more than ten-year practice, results of clinical trials and concordance studies. The GEFPICS group, composed of expert pathologists in breast cancer, herein presents these recommendations, adapted to the French routine practice. These guidelines highlight the possible diagnosis difficulties with regards to HER2 status determination, such as intra-tumor heterogeneity, special histological subtypes and biomarker re-evaluation during metastatic relapse. Pre-analytical issues and updated scoring criteria (especially for equivocal cases) are detailed, in order to decrease the occurrence of false negative cases. In the era of personalized medicine, pathologists are more than ever involved in the quality of oncotheranostic biomarker evaluation.
Recommandations du GEFPICS concernant la phase prĂ©-analytique pour lâĂ©valuation de HER2 et des rĂ©cepteurs hormonaux dans le cancer du sein : mise Ă jour 2014
Les tumeurs fixĂ©es et incluses en paraffine sont quotidiennement utilisĂ©es pour lâĂ©valuation des biomarqueurs nĂ©cessaires au traitement des patientes atteintes dâun cancer du sein invasif. Les nouvelles recommandations internationales sur la phase prĂ©-analytique ont Ă©tĂ© rĂ©cemment revues, confirmant lâimportance de la prise en charge optimale des prĂ©lĂšvements pour garantir des tests dâimmunohistochimie ou dâhybridation in situ de qualitĂ©, quel que soit le biomarqueur envisagĂ©. Incluant les procĂ©dĂ©s de fixation et de prĂ©paration des tissus, toutes les procĂ©dures prĂ©-analytiques doivent ĂȘtre validĂ©es, standardisĂ©es et tracĂ©es. Elles nĂ©cessitent la collaboration et la formation de toutes les personnes impliquĂ©es dans le circuit du prĂ©lĂšvement, du prĂ©leveur jusquâau technicien de pathologie et au pathologiste en passant par lâinfirmiĂšre, ou le coursier. La prise en charge initiale optimale des piĂšces et une fixation de qualitĂ© sont des Ă©tapes majeures Ă maĂźtriser dans la phase prĂ©-analytique. Cette mise Ă jour des recommandations du groupe dâĂ©tude des facteurs pronostiques immunohistochimiques dans le cancer du sein (GEFPICS) dĂ©taille et commente les diffĂ©rentes Ă©tapes prĂ©-analytiques. Lâobservation de ces rĂšgles de bonne pratique, lâutilisation rigoureuse de tĂ©moins internes et externes et la participation rĂ©guliĂšre Ă des programmes dâassurance qualitĂ© sont autant de garanties pour une Ă©valuation correcte et pĂ©renne des biomarqueurs oncothĂ©ranostiques., Summary Biomarker assessment of breast cancer tumor samples is part of the routine workflow of pathology laboratories. International guidelines have recently been updated, with special regards to the pre-analytical steps that are critical for the quality of immunohistochemical and in situ hybridization procedures, whatever the biomarker analyzed. Fixation and specimen handling protocols must be standardized, validated and carefully tracked. Cooperation and training of the personnel involved in the specimen workflow (e.g. radiologists, surgeons, nurses, technicians and pathologists) are of paramount importance. The GEFPICSâ update of the recommendations herein details and comments the different steps of the pre-analytical process. Application of these guidelines and participation to quality insurance programs are mandatory to ensure the correct evaluation of oncotheranostic biomarkers
Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future.
This study evaluated the consequences in Europe of the COVID-19 outbreak on pathology laboratories orientated toward the diagnosis of thoracic diseases.
A survey was sent to 71 pathology laboratories from 21 European countries. The questionnaire requested information concerning the organization of biosafety, the clinical and molecular pathology, the biobanking, the workload, the associated research into COVID-19, and the organization of education and training during the COVID-19 crisis, from 15 March to 31 May 2020, compared with the same period in 2019.
Questionnaires were returned from 53/71 (75%) laboratories from 18 European countries. The biosafety procedures were heterogeneous. The workload in clinical and molecular pathology decreased dramatically by 31% (range, 3%-55%) and 26% (range, 7%-62%), respectively. According to the professional category, between 28% and 41% of the staff members were not present in the laboratories but did teleworking. A total of 70% of the laboratories developed virtual meetings for the training of residents and junior pathologists. During the period of study, none of the staff members with confirmed COVID-19 became infected as a result of handling samples.
The COVID-19 pandemic has had a strong impact on most of the European pathology laboratories included in this study. Urgent implementation of several changes to the organization of most of these laboratories, notably to better harmonize biosafety procedures, was noted at the onset of the pandemic and maintained in the event of a new wave of infection occurring in Europe
Improvement in intramammary sentinel lymph node removal using a novel prototype hand held probe during breast conservative surgery
Brief communicationIntramammary sentinel lymph node excision during breast conservative surgery was performed, in this case report, using a prototype intraoperative gamma probe. In contrast to the four axillary sentinel lymph nodes that were subnormal, the excise intramammary sentinel lymph node was massively invaded by cancer cells. Therefore this finding had profound implication for the staging of the tumor and for treatment selection. This case report illustrates that an efficient intraoperative gamma probe is useful to locate and remove intramammary sentinel lymph node in breast cancer patients treated with breast conservatio